This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Polizzi, D. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Polizzi, D. Articles by Zunino, F.

A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts¹

Division of Experimental Oncology B, Istituto Nazionale Tumori, 20133 Milan [D. P., G. P., M. T., R. S., F. Z.]; and Indena S.p.A., 20139 Milan [A. R., E. B.], Italy

Clinically available taxanes represent one of the most promising class of antitumor agents, despite several problems with their solubility and toxicity. In an attempt to improve the pharmacological profile of taxanes, a new series of analogues was synthesized from 14ß-hydroxy-10-deacetylbaccatin III and tested in a panel of human tumor cell lines. On the basis of the pattern of cytotoxicity and lack of cross-resistance in tumor cell lines expressing the typical multidrug-resistant phenotype, a compound (IDN5109) was selected for preclinical development. A comparative efficacy study of IDN5109 and paclitaxel was performed using a large panel of human tumor xenografts, characterized by intrinsic (seven tumors) or acquired (four tumors) resistance to cisplatin or doxorubicin, including four ovarian, one breast, one cervical, three lung, one colon, and one prostatic carcinoma. Drugs were delivered i.v. according to the same schedule (four times every 4th day). IDN5109 achieved a very high level of activity (percentage tumor weight inhibition > 70%; log₁₀ cell kill > 1) in all but one of the tested tumors. Compared to paclitaxel, IDN5109 exhibited a significantly superior activity in six tumors (including the four tumors that were resistant to paclitaxel) and a comparable activity against the other five paclitaxel-responsive tumors. Additional advantages of IDN5109 over paclitaxel were also suggested by its toxicity profile. IDN5109 was not only less toxic (maximal tolerated doses were 90 and 54 mg/kg for IDN5109 and paclitaxel, respectively), but it also appeared to be endowed with a reduced neurotoxic potential and an improved profile of tolerability compared to the parent drug. Furthermore, the best antitumor efficacy was often already reached with doses lower than the maximal tolerated dose, suggesting an improved therapeutic index for the new drug. In conclusion, the results support the preclinical interest of IDN5109 in terms of the toxicity profile and of the efficacy with particular reference to the ability to overcome multiple mechanisms of drug resistance.

This article has been cited by other articles:

				C. Pisano, M. De Cesare, G. L. Beretta, V. Zuco, G. Pratesi, S. Penco, L. Vesci, R. Fodera, F. F. Ferrara, M. B. Guglielmi, et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968 Mol. Cancer Ther., July 1, 2008; 7(7): 2051 - 2059. [Abstract] [Full Text] [PDF]

				K. L. Hennenfent and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Onc., May 1, 2006; 17(5): 735 - 749. [Abstract] [Full Text] [PDF]

				D. Sampath, C. M. Discafani, F. Loganzo, C. Beyer, H. Liu, X. Tan, S. Musto, T. Annable, P. Gallagher, C. Rios, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo Mol. Cancer Ther., September 1, 2003; 2(9): 873 - 884. [Abstract] [Full Text] [PDF]

				G. Cassinelli, C. Lanzi, R. Supino, G. Pratesi, V. Zuco, D. Laccabue, G. Cuccuru, E. Bombardelli, and F. Zunino Cellular Bases of the Antitumor Activity of the Novel Taxane IDN 5109 (BAY59-8862) on Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2647 - 2654. [Abstract] [Full Text] [PDF]

				G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B. Maria Veneziani, F. Zunino, A. R. Bianco, and F. Ciardiello Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity Clin. Cancer Res., December 1, 2001; 7(12): 4156 - 4163. [Abstract] [Full Text] [PDF]

				S. Jennewein, C. D. Rithner, R. M. Williams, and R. B. Croteau Taxol biosynthesis: Taxane 13alpha -hydroxylase is a cytochrome P450-dependent monooxygenase PNAS, November 9, 2001; (2001) 251539398. [Abstract] [Full Text] [PDF]

				M. De Cesare, G. Pratesi, P. Perego, N. Carenini, S. Tinelli, L. Merlini, S. Penco, C. Pisano, F. Bucci, L. Vesci, et al. Potent Antitumor Activity and Improved Pharmacological Profile of ST1481, a Novel 7-substituted Camptothecin Cancer Res., October 1, 2001; 61(19): 7189 - 7195. [Abstract] [Full Text] [PDF]

				M. R. Vredenburg, I. Ojima, J. Veith, P. Pera, K. Kee, F. Cabral, A. Sharma, P. Kanter, W. R. Greco, and R. J. Bernacki Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance J Natl Cancer Inst, August 15, 2001; 93(16): 1234 - 1245. [Abstract] [Full Text] [PDF]

				D. Polizzi, G. Pratesi, S. Monestiroli, M. Tortoreto, F. Zunino, E. Bombardelli, A. Riva, P. Morazzoni, T. Colombo, M. D'Incalci, et al. Oral Efficacy and Bioavailability of a Novel Taxane Clin. Cancer Res., May 1, 2000; 6(5): 2070 - 2074. [Abstract] [Full Text] [PDF]

				M. I. Nicoletti, T. Colombo, C. Rossi, C. Monardo, S. Stura, M. Zucchetti, A. Riva, P. Morazzoni, M. B. Donati, E. Bombardelli, et al. IDN5109, a Taxane with Oral Bioavailability and Potent Antitumor Activity Cancer Res., February 1, 2000; 60(4): 842 - 846. [Abstract] [Full Text]

				S. Jennewein, C. D. Rithner, R. M. Williams, and R. B. Croteau Taxol biosynthesis: Taxane 13alpha -hydroxylase is a cytochrome P450-dependent monooxygenase PNAS, November 20, 2001; 98(24): 13595 - 13600. [Abstract] [Full Text] [PDF]